Intuitive Surgical, Inc.

Intuitive Surgical, Inc. is an American medical technology company that designs, manufactures, and markets robotic-assisted surgical systems, instruments, and diagnostic platforms — principally the da Vinci surgical system and the Ion endoluminal system — generating $10.06 billion in revenue in fiscal 2025. Headquartered in Sunnyvale, California, the company has placed more than 10,000 da Vinci systems worldwide and its platforms were used in over 3 million procedures in 2025, making it the dominant force in robotic surgery by a wide margin.

This is a story about an extraordinary business that the market already knows is extraordinary. Intuitive has spent two decades building a razor-and-blade model around a capital-equipment install base that generates 86% recurring revenue, with procedure volumes compounding in the mid-to-high teens and a fifth-generation system (da Vinci 5) that is demonstrably better than its predecessor. The file turns on a harder question: whether that excellence is durable enough to justify the price. At roughly $147 billion in market capitalization, the stock embeds expectations that procedure growth stays elevated, competition remains contained, and margins expand from here — assumptions that each deserve scrutiny even if none looks obviously wrong today.

The bull case is straightforward and well-understood: robotic surgery penetration is still low across most procedure categories and geographies, Intuitive's ecosystem creates genuine switching costs, and da Vinci 5's force-feedback and digital capabilities widen a moat that has held for 25 years. The bear case is harder to articulate without sounding foolish — betting against Intuitive has been a losing trade — but it rests on the observation that every durable franchise eventually faces a moment when growth decelerates into a multiple that doesn't support the prior valuation. Whether that moment is near or distant is what this file tries to help you judge.